26 Aug
2021

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

Pfizer’s big-ticket acquisition of cutting-edge immuno-therapy inventions is the most recent development in the booming oncology IP market.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth